Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review

Background and ObjectivePrecision (stratified or personalised) medicine is underpinned by the premise that it is feasible to identify known heterogeneity using a specific test or algorithm in patient populations and to use this information to guide patient care to improve health and well-being. This study aimed to understand if, and how, previous economic evaluations of precision medicine had taken account of the impact of capacity constraints.MethodsA meta-review was conducted of published systematic reviews of economic evaluations of precision medicine (test–treat interventions) and individual studies included in these reviews. Due to the volume of studies identified, a sample of papers published from 2007 to 2015 was collated. A narrative analysis identified whether potential capacity constraints were discussed qualitatively in the studies and, if relevant, which quantitative methods were used to account for capacity constraints.ResultsA total of 45 systematic reviews of economic evaluations of precision medicine were identified, from which 222 studies focusing on test–treat interventions, published between 2007 and 2015, were extracted. Of these studies, 33 (15%) qualitatively discussed the potential impact of capacity constraints, including budget constraints; quality of tests and the testing process; ease of use of tests in clinical practice; and decision uncertainty. Quantitative methods (nine studies) to account for capacity constraints included static methods such as capturing inefficiencies in trials or models and sensitivity analysis around model parameters; and dynamic methods, which allow the impact of capacity constraints on cost effectiveness to change over time.ConclusionsUnderstanding the cost effectiveness of precision medicine is necessary, but not sufficient, evidence for its successful implementation. There are currently few examples of evaluations that have quantified the impact of capacity constraints, which suggests an area of focus for future research.

[1]  Michel Wensing,et al.  Economic barriers to implementation of innovations in health care: is the long run-short run efficiency discrepancy a paradox? , 2008, Health policy.

[2]  E. Adang,et al.  Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. , 2005, Health policy.

[3]  Jerry Avorn,et al.  Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation , 2009, Circulation. Cardiovascular quality and outcomes.

[4]  Julie Ratcliffe,et al.  Bridging the Gap: Exploring the Barriers to Using Economic Evidence in Healthcare Decision Making and Strategies for Improving Uptake , 2015, Applied Health Economics and Health Policy.

[5]  Jean-Paul Moatti,et al.  Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer , 2009, American journal of clinical oncology.

[6]  Karl Claxton,et al.  The Value of Implementation and the Value of Information: Combined and Uneven Development , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  C. Sutton,et al.  Developing and evaluating complex interventions. , 2014, Maternal & child nutrition.

[8]  Katherine Payne,et al.  Cost-effectiveness analyses of genetic and genomic diagnostic tests , 2018, Nature Reviews Genetics.

[9]  L. Wilton,et al.  The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. , 2015, Human reproduction.

[10]  M. Lux,et al.  Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model , 2009, Breast Cancer Research and Treatment.

[11]  P O Collinson,et al.  Randomised Assessment of Treatment using Panel Assay of Cardiac markers--Contemporary Biomarker Evaluation (RATPAC CBE). , 2013, Health technology assessment.

[12]  Mehdi Najafzadeh,et al.  Barriers for integrating personalized medicine into clinical practice: A qualitative analysis , 2013, American journal of medical genetics. Part A.

[13]  Carlos Crespo,et al.  Genomic profile of breast cancer: cost–effectiveness analysis from the Spanish National Healthcare System perspective , 2014, Expert review of pharmacoeconomics & outcomes research.

[14]  T. Delea,et al.  Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer , 2013, Breast Care.

[15]  A F Monk,et al.  ASSESSMENT OF THE LEARNING CURVE IN HEALTH TECHNOLOGIES , 2000, International Journal of Technology Assessment in Health Care.

[16]  Paul Keown,et al.  Cost‐Effectiveness of Organ Donation: Evaluating Investment into Donor Action and Other Donor Initiatives , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  Katherine Payne,et al.  Removing barriers to a clinical pharmacogenetics service. , 2008, Personalized medicine.

[18]  David Cameron,et al.  Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab , 2012, The European Journal of Health Economics.

[19]  Kenneth A. Freedberg,et al.  Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial , 2012, AIDS.

[20]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[21]  Murray Krahn,et al.  Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Michael Hauptmann,et al.  Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. , 2010, European journal of cancer.

[23]  Niteesh Choudhry,et al.  Cost‐effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer , 2013, Cancer.

[24]  Scott D Ramsey,et al.  Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). , 2008, Lung cancer.

[25]  A. Rademaker,et al.  Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: A call for dialogue , 2009, Genetics in Medicine.

[26]  Katherine Payne,et al.  The economic case for precision medicine , 2018, Expert review of precision medicine and drug development.

[27]  Antonis C. Antoniou,et al.  Cost‐effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry , 2017, American journal of obstetrics and gynecology.

[28]  M. Broder,et al.  Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. , 2011, The American journal of managed care.

[29]  D. Petrie,et al.  The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study , 2013, British Journal of Cancer.

[30]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[31]  J. Hochman,et al.  Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost‐effectiveness analysis , 2013, Journal of thrombosis and haemostasis : JTH.

[32]  Katherine Payne,et al.  The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  L. Mantovani,et al.  KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting , 2014, PloS one.

[34]  Medical Advisory Secretariat Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. , 2010, Ontario health technology assessment series.

[35]  C Proudlove,et al.  Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. , 2010, Health technology assessment.

[36]  M Sculpher,et al.  Evaluating the cost-effectiveness of interventions designed to increase the utilization of evidence-based guidelines. , 2000, Family practice.

[37]  Willem H Woertman,et al.  A model to correct for short-run inefficiencies in economic evaluations in healthcare. , 2012, Health economics.

[38]  Bernhard Holzner,et al.  Cost–utility analyses of drug therapies in breast cancer: a systematic review , 2016, Breast Cancer Research and Treatment.

[39]  Trevor A Sheldon,et al.  What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews , 2004, BMJ : British Medical Journal.

[40]  Louis P Garrison,et al.  The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[41]  Milton C Weinstein,et al.  Packaging Health Services When Resources Are Limited: The Example of a Cervical Cancer Screening Visit , 2006, PLoS medicine.

[42]  E. Adang,et al.  Economic evaluation of innovative technologies in health care should include a short-run perspective , 2008, The European Journal of Health Economics.

[43]  Ariel Hammerman,et al.  Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[44]  Matt Stevenson,et al.  Methods for handling uncertainty within pharmaceutical funding decisions , 2014, Int. J. Syst. Sci..

[45]  Bruce Wang,et al.  Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status , 2013, Cancer.

[46]  Eddy M. Adang,et al.  Time to incorporate time in cost-effectiveness analysis , 2012, The European Journal of Health Economics.

[47]  J. Bergh,et al.  Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  R Charles Coombes,et al.  Stratified, precision or personalised medicine? Cancer services in the 'real world' of a London hospital. , 2017, Sociology of Health and Illness.

[49]  Brent C Opmeer,et al.  Diagnostic strategies for endometrial cancer in women with postmenopausal bleeding: cost-effectiveness of individualized strategies. , 2012, European journal of obstetrics, gynecology, and reproductive biology.

[50]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.

[51]  Surasak Saokaew,et al.  Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population , 2014, PloS one.

[52]  Jade K. Forwood,et al.  Structural Characterization of a Gcn5-Related N-Acetyltransferase from Staphylococcus aureus , 2014, PloS one.

[53]  Gert Jan van der Wilt,et al.  UNDERSTANDING AND ANTICIPATING LAG-TIME BIAS IN COST-EFFECTIVENESS STUDIES: THE ROLE OF TIME IN COST-EFFECTIVENESS ANALYSIS , 2014, International Journal of Technology Assessment in Health Care.

[54]  Stuart Peacock,et al.  Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  Ron Goeree,et al.  Capacity Constraints and Cost-Effectiveness: A Discrete Event Simulation for Drug-Eluting Stents , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[56]  David W. Dowdy,et al.  Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making , 2014, PloS one.

[57]  Julie Sakowski,et al.  Economic Perspectives on Personalized Health Care and Prevention , 2013, Forum for health economics & policy.

[58]  Alastair Fischer,et al.  Health care resource allocation: is the threshold rule good enough? , 2004, Journal of health services research & policy.

[59]  Valesca P Retèl,et al.  Scenario drafting to anticipate future developments in technology assessment , 2012, BMC Research Notes.

[60]  Gary H Lyman,et al.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. , 2005, The American journal of managed care.

[61]  A. Hughes Oxford English Dictionary. , 2008, Isis; an international review devoted to the history of science and its cultural influences.

[62]  Tae-Jin Lee,et al.  Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context , 2010 .

[63]  W. Gradishar,et al.  Barriers to the use of personalized medicine in breast cancer. , 2012, Journal of oncology practice.

[64]  Karl Claxton,et al.  Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[65]  Hiroshi Ishiguro,et al.  Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan , 2008, Breast Cancer Research and Treatment.

[66]  David Cutler,et al.  Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer , 2015 .

[67]  J. Severens,et al.  Value for money of changing healthcare services? Economic evaluation of quality improvement , 2003, Quality & safety in health care.

[68]  John Hornberger,et al.  US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer. , 2011, Journal of oncology practice.

[69]  M. Villasís-Keever,et al.  A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours , 2008, British Journal of Cancer.

[70]  E. Pearson Personalized medicine in diabetes: the role of ‘omics’ and biomarkers , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[71]  Gijs van de Wetering,et al.  Quantifying short run cost-effectiveness during a gradual implementation process , 2013, The European Journal of Health Economics.

[72]  Medical Advisory Secretariat Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. , 2010, Ontario health technology assessment series.